JP2013530160A - 赤血球増加症治療用ａｎｔｉｍｉＲ−４５１ - Google Patents

赤血球増加症治療用ａｎｔｉｍｉＲ−４５１ Download PDF

Info

Publication number
JP2013530160A
JP2013530160A JP2013512611A JP2013512611A JP2013530160A JP 2013530160 A JP2013530160 A JP 2013530160A JP 2013512611 A JP2013512611 A JP 2013512611A JP 2013512611 A JP2013512611 A JP 2013512611A JP 2013530160 A JP2013530160 A JP 2013530160A
Authority
JP
Japan
Prior art keywords
mir
seq
sequence
antisense oligonucleotide
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013512611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530160A5 (enExample
Inventor
エヌ． オルソン，エリック
エム． パトリック，デイヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2013530160A publication Critical patent/JP2013530160A/ja
Publication of JP2013530160A5 publication Critical patent/JP2013530160A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013512611A 2010-01-20 2011-01-20 赤血球増加症治療用ａｎｔｉｍｉＲ−４５１ Pending JP2013530160A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29678310P 2010-01-20 2010-01-20
US61/296,783 2010-01-20
US28254610P 2010-02-26 2010-02-26
US61/282,546 2010-02-26
PCT/US2011/021886 WO2012148373A1 (en) 2010-01-20 2011-01-20 Antimir-451 for the treatment of polycythemias

Publications (2)

Publication Number Publication Date
JP2013530160A true JP2013530160A (ja) 2013-07-25
JP2013530160A5 JP2013530160A5 (enExample) 2014-03-06

Family

ID=47072618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013512611A Pending JP2013530160A (ja) 2010-01-20 2011-01-20 赤血球増加症治療用ａｎｔｉｍｉＲ−４５１

Country Status (5)

Country Link
US (1) US9340782B2 (enExample)
EP (1) EP2536436A4 (enExample)
JP (1) JP2013530160A (enExample)
CN (1) CN102869386A (enExample)
WO (1) WO2012148373A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970968B1 (en) 2013-03-15 2018-01-10 Miragen Therapeutics, Inc. Bridged bicyclic nucleosides
WO2016094406A1 (en) * 2014-12-08 2016-06-16 Thomas Jefferson University Treatment and prevention of thrombosis using an anti-mir
US10306081B2 (en) * 2015-07-09 2019-05-28 Turner Broadcasting System, Inc. Technologies for generating a point-of-view video
ES2659845B1 (es) 2016-09-19 2019-01-04 Univ Valencia Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
CN113332434B (zh) * 2021-05-25 2023-09-05 大连医科大学 miR-451a调节剂在制备调控血压制剂中的应用
EP4506010A1 (en) 2022-04-06 2025-02-12 Universitat de València Antagonists of human micro rna mir-100, mir-20, mir-222, mir-181 and mir-92 and uses of same
CN115920054A (zh) * 2022-12-23 2023-04-07 扬州大学 miR-144/451作为靶点在治疗精神分裂症中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539699A (ja) * 2005-04-29 2008-11-20 ザ ロックフェラー ユニバーシティ マイクロｒｎａ及びそれを阻害する方法
US20090326051A1 (en) * 2008-06-04 2009-12-31 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
EP2285960B1 (en) 2008-05-08 2015-07-08 Asuragen, INC. Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539699A (ja) * 2005-04-29 2008-11-20 ザ ロックフェラー ユニバーシティ マイクロｒｎａ及びそれを阻害する方法
US20090326051A1 (en) * 2008-06-04 2009-12-31 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6015000530; ＰＡＳＥ，　Ｌ　ｅｔ　ａｌ，　ＢＬＯＯＤ，　２００９，　ｖｏｌ．１１３，　ｎｏ．８，　ｐ．１７９４-８０４ *
JPN6015000532; ＬＯＩＳ，　ＣＤ　ｅｔ　ａｌ，　ＰＮＡＳ，　２００８，　ｖｏｌ．１０５，　ｎｏ．９，　ｐ．３３３３-８ *
JPN6015000537; ＺＨＡＮ，　Ｍ　ｅｔ　ａｌ，　Ｅｘｐ　Ｈｅｍａｔｏｌ，　２００７，　ｖｏｌ．３５，　ｎｏ．７，　ｐ．１０１５-２５ *
JPN6015000540; ＢＲＵＣＨＯＶＡ，　Ｈ　ｅｔ　ａｌ，　Ｅｘｐ　Ｈｅｍａｔｏｌ，　２００７，　ｖｏｌ．３５，　ｎｏ．１１，　ｐ．１６５７-６７ *
JPN6015000542; ＢＲＵＣＨＯＶＡ，　Ｈ　ｅｔ　ａｌ，　ＢＬＯＯＤ，　２００６，　ｖｏｌ．１０８，　ｎｏ．１１，　Ａｂｓｔｒａｃｔ　３６１３ *
JPN6015000544; 福島雅典監修，　メルクマニュアル第１８版日本語版，　２００６，　ｐ．１１６２-６ *

Also Published As

Publication number Publication date
CN102869386A (zh) 2013-01-09
US20140011859A1 (en) 2014-01-09
EP2536436A4 (en) 2015-01-14
US9340782B2 (en) 2016-05-17
WO2012148373A1 (en) 2012-11-01
EP2536436A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
KR101965868B1 (ko) 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
US9340782B2 (en) Antimir-451 for the treatment of polycythemias
AU2018329190A1 (en) RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
AU2014318580A1 (en) Modulators of Complement Factor B
WO2017024111A1 (en) Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
US20190300881A1 (en) Method of treatment
CN101273130B (zh) 用于下调h19的核酸物质及其使用方法
KR20220158011A (ko) PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
US9885043B2 (en) Methods for inducing cardiomyocyte proliferation
US20240415980A1 (en) Crispr/cas-related methods and compositions for knocking out c5
CA2784918A1 (en) Antimir-451 for the treatment of polycythemias
WO2023028085A2 (en) Antisense oligonucleotide therapy for h3.3 k27m diffuse midline gliomas
WO2025147604A1 (en) Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1
EP4558635A2 (en) Methods and compositions for selectively modulating gene expression in megakaryocytes and platelets
HK40000192B (en) Compositions and methods for modulation of smn2 splicing in a subject
HK40000192A (en) Compositions and methods for modulation of smn2 splicing in a subject

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150814